InflaRx (IFRX) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Key product developments and differentiation

• Izicopan, an oral C5aR antagonist, shows higher bioavailability, faster onset, and lower CYP3A4 inhibition compared to avacopan, suggesting improved safety and efficacy profiles.

• No hepatotoxicity or significant safety issues observed in approximately 200 patients treated with izicopan, even at high doses.

• Izicopan’s rapid achievement of therapeutic levels and clean safety profile position it as a potentially best-in-class molecule.

• The molecule’s unique reduction of draining tunnels and pain in HS patients may indicate a differentiated mechanism of action.

Clinical trial progress and future plans

• Proof-of-concept phase IIA basket study in HS and CSU showed encouraging efficacy signals, especially in high-dose groups.

• Long-term toxicology data now available, enabling indefinite dosing and supporting advancement to phase IIB trials.

• Ongoing discussions with regulators and key opinion leaders to finalize phase IIB trial design, endpoints, and dosing.

• Phase IIB trial required before proceeding to pivotal phase III; trial design will address optimal dosing and endpoints.

Market landscape and strategic opportunities

• Potential market opportunity if avacopan is withdrawn, as izicopan’s safety and efficacy could fill the gap.

• HS remains the primary focus, but CSU is also promising, with particularly good results in severe CSU and angioedema subsets.

• Commercial success in HS will depend on matching or exceeding injectable biologics’ efficacy and maintaining a strong safety profile.

• Regulatory discussions are ongoing to define endpoints that reflect clinical benefits, especially for draining tunnels.